- Link to News & Events page from breadcrumb
- Portfolio news
Portfolio news .
Tissue Regenix Group plc
Notice of Results
02 Mar 2022
Tissue Regenix (AIM: TRX), the regenerative medical devices company, will announce its final results for the year ended 31 December 2021 on Tuesday 15 March 2022.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will be hosting a live online presentation relating to the final results via the Investor Meet Company platform at 4.30pm on Tuesday 15 March 2022. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.
For more information:
Tissue Regenix Group plc |
Via Walbrook PR |
David Cocke, Chief Financial Officer |
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) |
Tel: +44(0)20 7710 7600 |
Ben Maddison / Alex Price / Nicholas Harland |
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 |
Alice Woodings / Lianne Cawthorne |
|
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.